Moreover, the evaluation of the genetic signature of each tumor and the identification of polymorphisms associated with immune response in patients, especially those involved in IFN-γ and CD38-dependent mechanisms, may provide a relevant tool to identify patients at risk of developing HPD. This evidence concerns the gene IFNG and neoplasm.